Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Rating of “Moderate Buy” by Analysts

Allogene Therapeutics, Inc. (NASDAQ:ALLO) has been given a consensus rating of “Moderate Buy” by the ten analysts that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $9.95.

ALLO has been the subject of a number of recent research reports. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of Allogene Therapeutics in a report on Friday, March 15th. Oppenheimer lowered their target price on shares of Allogene Therapeutics from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Tuesday, May 21st. HC Wainwright reduced their price target on Allogene Therapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, May 16th. Stifel Nicolaus lifted their price objective on Allogene Therapeutics from $4.40 to $4.60 and gave the company a “hold” rating in a research report on Tuesday, May 14th. Finally, Truist Financial reissued a “buy” rating and issued a $17.00 price target on shares of Allogene Therapeutics in a research note on Wednesday, May 15th.

Insider Transactions at Allogene Therapeutics

In related news, Director Arie Belldegrun purchased 1,724,137 shares of Allogene Therapeutics stock in a transaction dated Thursday, May 16th. The shares were acquired at an average price of $2.90 per share, with a total value of $4,999,997.30. Following the completion of the transaction, the director now owns 1,724,137 shares of the company’s stock, valued at approximately $4,999,997.30. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. In other Allogene Therapeutics news, Director Franz B. Humer sold 11,200 shares of Allogene Therapeutics stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $2.34, for a total value of $26,208.00. Following the completion of the transaction, the director now owns 255,253 shares of the company’s stock, valued at $597,292.02. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Arie Belldegrun bought 1,724,137 shares of the stock in a transaction on Thursday, May 16th. The shares were acquired at an average price of $2.90 per share, with a total value of $4,999,997.30. Following the purchase, the director now owns 1,724,137 shares of the company’s stock, valued at $4,999,997.30. The disclosure for this purchase can be found here. Corporate insiders own 24.30% of the company’s stock.

Hedge Funds Weigh In On Allogene Therapeutics

A number of large investors have recently bought and sold shares of ALLO. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Allogene Therapeutics during the 4th quarter worth approximately $27,000. Axxcess Wealth Management LLC bought a new position in Allogene Therapeutics during the 4th quarter worth $34,000. Aaron Wealth Advisors LLC acquired a new stake in Allogene Therapeutics in the fourth quarter worth $34,000. EP Wealth Advisors LLC acquired a new stake in shares of Allogene Therapeutics in the 3rd quarter worth about $34,000. Finally, Victory Capital Management Inc. boosted its stake in Allogene Therapeutics by 23.1% during the 4th quarter. Victory Capital Management Inc. now owns 14,283 shares of the company’s stock valued at $46,000 after purchasing an additional 2,680 shares during the period. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Trading Down 4.5 %

Shares of ALLO opened at $2.33 on Wednesday. The company has a 50-day moving average of $2.65 and a two-hundred day moving average of $3.50. The stock has a market cap of $486.97 million, a P/E ratio of -1.30 and a beta of 0.86. Allogene Therapeutics has a 12-month low of $2.18 and a 12-month high of $6.05.

Allogene Therapeutics (NASDAQ:ALLO) last posted its earnings results on Monday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.01 million. Allogene Therapeutics had a negative return on equity of 50.81% and a negative net margin of 223,139.98%. Allogene Therapeutics’s revenue was down 26.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.68) EPS. As a group, analysts forecast that Allogene Therapeutics will post -1.5 EPS for the current fiscal year.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).